Open Access
Issue
E3S Web of Conf.
Volume 553, 2024
2024 International Conference on Ecological Protection and Environmental Chemistry (EPEC 2024)
Article Number 05044
Number of page(s) 6
Section Medical Treatments and Therapies
DOI https://doi.org/10.1051/e3sconf/202455305044
Published online 24 July 2024
  1. D. Gouglas, T. Thanh Le, K. Henderson, A. Kaloudis, T. Danielsen, N.C. Hammersland, J.M. Robinson, P.M. Heaton, J.-A. Røttingen, Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study, The Lancet Global Health 6(12) (2018) e1386-e1396. [Google Scholar]
  2. O.o.I.D. Policy, Hiv/Aids, Vaccine Side Effects, HHS.gov (2021). [Google Scholar]
  3. M. Trovato, R. Sartorius, L. D’Apice, R. Manco, P. De Berardinis, Viral Emerging Diseases: Challenges in Developing Vaccination Strategies, Frontiers in Immunology 11 (2020). [Google Scholar]
  4. B. Kapingidza, D.J. Marston, C. Harris, D. Wrapp, K. Winters, B. Rhodes, P. Vure, C.W. Woods, E.A. Petzold, E.B. Walter, R. Parks, M. Barr, Q. Yin, D.W. Cain, K. Wiehe, K.O. Saunders, B.F. Haynes, M.L. Azoitei, Engineered Immunogens to Expose Conserved Epitopes Targeted by Broad Coronavirus Antibodies, bioRxiv: The Preprint Server for Biology (2023) 2023.02.27.530277. [Google Scholar]
  5. M.L. Paull, T. Johnston, K.N. Ibsen, J.D. Bozekowski, P.S. Daugherty, A general approach for predicting protein epitopes targeted by antibody repertoires using whole proteomes, PLoS ONE 14(9) (2019). [Google Scholar]
  6. R.L. Coffman, A. Sher, R.A. Seder, Vaccine Adjuvants: Putting Innate Immunity to Work, Immunity 33(4) (2010). 492-503. [Google Scholar]
  7. B. Pulendran, P. S. Arunachalam, D.T. O’Hagan, Emerging concepts in the science of vaccine adjuvants, Nature Reviews Drug Discovery 20(6) (2021) 454-475. [CrossRef] [PubMed] [Google Scholar]
  8. E.J. Wherry, D.H. Barouch, T cell immunity to COVID-19 vaccines, Science 377(6608) (2022) 821-822. [Google Scholar]
  9. Y. Janssens, J. Joye, G. Waerlop, F. Clement, G. Leroux-Roels, I. Leroux-Roels, The role of cell-mediated immunity against influenza and its implications for vaccine evaluation, Frontiers in Immunology 13 (2022) 959379. [Google Scholar]
  10. K.-H. Kim, Z. Li, N. Bhatnagar, J. Subbiah, B.R. Park, C.H. Shin, P. Pushko, B.-Z. Wang, S.-M. Kang, Universal protection against influenza viruses by multi-subtype neuraminidase and M2 ectodomain virus-like particle, PLOS Pathogens 18(8) (2022) e1010755. [Google Scholar]
  11. S. Rauch, E. Jasny, K.E. Schmidt, B. Petsch, New Vaccine Technologies to Combat Outbreak Situations, Frontiers in Immunology 9 (2018). [Google Scholar]
  12. N. Chaudhary, D. Weissman, K.A. Whitehead, mRNA vaccines for infectious diseases: principles, delivery and clinical translation, Nature Reviews Drug Discovery 20(11) (2021). [Google Scholar]
  13. F. Wu, S. Zhao, B. Yu, Y.-M. Chen, W. Wang, Z.-G. Song, Y. Hu, Z.-W. Tao, J.-H. Tian, Y.-Y. Pei, M.-L. Yuan, Y.-L. Zhang, F.-H. Dai, Y. Liu, Q.-M. Wang, J.-J. Zheng, L. Xu, E.C. Holmes, Y.-Z. Zhang, A new coronavirus associated with human respiratory disease in China, Nature 579(7798) (2020). [Google Scholar]
  14. L.R. Baden, H.M. El Sahly, B. Essink, Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine, New England Journal of Medicine 384(5) (2020) 403-416. [Google Scholar]
  15. S.S. Dutta, What is a Non-Replicating Vaccine?, News-Medical.net (2020). [Google Scholar]
  16. M. Robert-Guroff, Replicating and non-replicating viral vectors for vaccine development, Current Opinion in Biotechnology 18(6) (2007) 546-556. [Google Scholar]
  17. S. Matias, F. Sugiyama, G. Humberto Doriguêtto, F.J. Mercado, J. Oliveira, C. Fontanari, F. Fabiani Gai, COVID-19 inactivated and non-replicating viral vector vaccines induce regulatory training phenotype in human monocytes under epigenetic control, Frontiers in Cellular and Infection Microbiology 13 (2023). [Google Scholar]
  18. G.L. Rosano, E.A. Ceccarelli, Recombinant protein expression in Escherichia coli: Advances and challenges, Frontiers in Microbiology 5(172) (2014). [Google Scholar]
  19. K.K. Morgan, Variants of Coronavirus, WebMD (2023). [Google Scholar]
  20. W. Feng, Y. Xiang, L. Wu, Z. Chen, Q. Li, J. Chen, Y. Guo, D. Xia, N. Chen, L. Zhang, S. Zhu, K.N. Zhao, Nucleocapsid protein of SARS‐CoV‐2 is a potential target for developing new generation of vaccine, Journal of Clinical Laboratory Analysis 36(6) (2022). [Google Scholar]
  21. J.-T. Jan, T.-J.R. Cheng, Y.-P. Juang, H.-H. Ma, Y.-T. Wu, W.-B. Yang, C.-W. Cheng, X. Chen, T.- H. Chou, J.-J. Shie, W.-C. Cheng, R.-J. Chein, S.-S. Mao, P.-H. Liang, C. Ma, S.-C. Hung, C.-H. Wong, Identification of existing pharmaceuticals and herbal medicines as inhibitors of SARS-CoV-2 infection, Proceedings of the National Academy of Sciences 118(5) (2021). [Google Scholar]
  22. M.-Y. Wang, R. Zhao, L.-J. Gao, X.-F. Gao, D.-P. Wang, J.-M. Cao, SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development, Frontiers in Cellular and Infection Microbiology 10(587269) (2020). [Google Scholar]
  23. D. Kim, J.-Y. Lee, J.-S. Yang, J.W. Kim, V.N. Kim, H. Chang, The Architecture of SARS-CoV-2 Transcriptome, Cell 181(4) (2020). [Google Scholar]
  24. S. Venkataraman, B. Prasad, R. Selvarajan, RNA Dependent RNA Polymerases: Insights from Structure, Function and Evolution, Viruses 10(2) (2018) 76. [Google Scholar]
  25. F. Krammer, G.J.D. Smith, R.A.M. Fouchier, M. Peiris, K. Kedzierska, P.C. Doherty, P. Palese, M.L. Shaw, J. Treanor, R.G. Webster, A. García-Sastre, Influenza, Nature Reviews Disease Primers 4(1) (2018). [Google Scholar]
  26. D.S. Rajão, D.R. Pérez, Universal Vaccines and Vaccine Platforms to Protect against Influenza Viruses in Humans and Agriculture, Frontiers in Microbiology 9 (2018). [Google Scholar]
  27. W.-C. Wang, E.E. Sayedahmed, S. Sambhara, S.K. Mittal, Progress towards the Development of a Universal Influenza Vaccine, Viruses 14(8) (2022) 1684. [CrossRef] [PubMed] [Google Scholar]
  28. K. Subbarao, Y. Matsuoka, The prospects and challenges of universal vaccines for influenza, Trends in Microbiology 21(7) (2013) 350-358. [CrossRef] [PubMed] [Google Scholar]
  29. C.-J. Wei, M.C. Crank, J. Shiver, B.S. Graham, J.R. Mascola, G.J. Nabel, Next-generation influenza vaccines: opportunities and challenges, Nature Reviews Drug Discovery 19(4) (2020) 239-252. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.